Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas

Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin®). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors.

• Publication year

  2004

• Venue

  British Journal of Cancer

• Publication date

  2004-08-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6602089PMID 15328518PMCID 2747695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Her-2/neu Overexpression and Clinical Determinants of Early Mortality in Glioblastoma Multiforme

  2003cited by this paper
• Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells

  2003cited by this paper
• Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.

  2002cited by this paper
• Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.

  2002cited by this paper
• Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

  2002cited by this paper
• HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

  2002cited by this paper
• [Glioblastomas: clinical study and search for prognostic factors].

  2002influential reference
• Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

  2001cited by this paper
• Transformation of donor‐derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy

  2001cited by this paper
• Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors.

  2000cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Tumeurs gliales de l'adulte

  1999cited by this paper
• Long-Term Survival in Cerebral Glioblastoma. Case Report and Critical Review of the Literature

  1998cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Characterization of Angiogenesis and Microcirculation of High–Grade Glioma: An Intravital Multifluorescence Microscopic Approach in the Athymic Nude Mouse

  1998cited by this paper
• Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival

  1997influential reference
• Heregulins and the ErbB-2/3/4 receptors in gliomas

  1997cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.

  1996cited by this paper
• Differences between phosphotyrosine accumulation and Neu/ErbB‐2 receptor expression in astrocytic proliferative processes: Implications for glial oncogenesis

  1996cited by this paper
• Fc receptor for IgG (FcR) on rat microglia.

  1994influential reference
• Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study.

  1994cited by this paper
• Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

  1993cited by this paper
• Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)

  1993cited by this paper
• Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.

  1993cited by this paper
• Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease.

  1993cited by this paper
• Identification of FcγRI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease

  1993cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992influential reference
• Persistent complement activation on tumor cells in breast cancer.

  1992cited by this paper
• Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

  1990cited by this paper
• Brain microglia constitutively express beta-2 integrins.

  1990cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper

• Pretargeted Polymeric Systems for Conducting Chemo-Radiotherapy on Glioblastoma: An Evaluation of the Impact of Nanomedicine Structure on Bioorthogonal Chemistry In Vivo.

  2025cites this paper
• Inhibitory effect of lomustine on the growth of spontaneous HER2-positive mammary tumors in transgenic mice

  2024cites this paper
• Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma.

  2023cites this paper
• A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers

  2023cites this paper
• High-Sensitivity Immunohistochemistry Method Using a Combination of Fluorescent Nanoparticles and Tyramide Linker

  2022cites this paper
• Immunotherapy in Pediatric Solid Tumors

  2020cites this paper
• A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response.

  2020cites this paper
• Curcumin-induced cell death depends on the level of autophagic flux in A172 and U87MG human glioblastoma cells.

  2020cites this paper
• Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications

  2020cites this paper
• Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates

  2019cites this paper
• Characterization of antibody-C1q interactions by Biolayer Interferometry.

  2018cites this paper
• New developments in immunotherapy for pediatric solid tumors

  2017cites this paper
• Immunotherapies for Malignant Glioma

  2017cites this paper
• CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity

  2017cites this paper
• Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma

  2017cites this paper
• HER2-targeted recombinant protein immuno-caspase-6 effectively induces apoptosis in HER2-overexpressing GBM cells in vitro and in vivo.

  2016cites this paper
• Tumor infiltrating immune cells in gliomas and meningiomas.

  2016cites this paper
• Glioma

  2015cites this paper
• [Gliomas and BRCA genes mutations: fortuitous association or imputability?].

  2014cites this paper
• Glioblastoma extracellular vesicles: reservoirs of potential biomarkers

  2014cites this paper
• [Modern molecular approaches to diagnosis and treatment of high-grade brain gliomas].

  2014cites this paper
• Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.

  2014cites this paper
• Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

  2014cites this paper
• Современные молекулярные подходы к диагностике и лечению низкодифференцированных глиом

  2014cites this paper
• Gliomes et mutations des gènes BRCA: association fortuite ou imputabilité?

  2014cites this paper
• Integrated Systems and Technologies Apoptosis Imaging for Monitoring DR 5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

  2014cites this paper
• Targeting the anti-inflammatory interplay promoting glioblastoma progression with combined natural killer cells and mab9.2.27 against NG2/CSPG4. A novel strategy to reveal glioblastoma to the immune system

  2013cites this paper
• Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies

  2013cites this paper
• Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

  2013cites this paper
• Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

  2012cites this paper
• Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

  2012cites this paper
• Monoclonal antibody therapy for malignant glioma.

  2012cites this paper
• A pathway profile-based method for drug repositioning

  2012cites this paper
• Study of drug function based on similarity of pathway fingerprint

  2012cites this paper
• Nanotechnology platforms; an innovative approach to brain tumor therapy.

  2011cites this paper
• Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody‐dependent cellular cytotoxicity of EGFR‐ and HER2‐overexpressing esophageal cancer cell lines

  2011cites this paper
• Current and emerging molecular targets in glioma

  2010cites this paper
• Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model

  2010cites this paper
• Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

  2010cites this paper
• Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics

  2009cites this paper
• Flow Cytometry Analysis of Neural Differentiation Markers Expression in Human Glioblastomas May Predict Their Response to Chemotherapy

  2009cites this paper
• Targeted therapy for malignant glioma patients: Lessons learned and the road ahead

  2009cites this paper
• Resistance to Trastuzumab in Breast Cancer

  2009cites this paper
• Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity

  2008cites this paper
• Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.

  2007cites this paper
• Low HER 2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

  2007cites this paper
• Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

  2007cites this paper
• Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

  2007cites this paper
• Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients

  2007cites this paper
• Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine

  2006cites this paper
• Multicentric Glioblastoma Multiforme in a Patient with BRCA‐1 Invasive Breast Cancer

  2006cites this paper
• Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme.

  2006cites this paper
• Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours

  2006cites this paper
• Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas

  2006cites this paper
• New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.

  2006cites this paper
• Increasing of HER2 Membranar Density in Human Glioblastoma U251MG Cell Line Established in a New Nude Mice Model

  2006cites this paper
• HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: An unexpected effect on TRAIL‐induced apoptosis

  2005cites this paper